Pentax 2011 Annual Report Download - page 49

Download and view the complete annual report

Please find page 49 of the 2011 Pentax annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

Fiscal 2011 Business Overview and Results Outlook for Fiscal 2012
Fiscal 2011 Business Overview and Results
In the fiscal year under review、 Japan's composite bone
market grew 3-4% in terms of patient numbers. However, the
market was nearly flat compared to the previous year on a
value basis due to medical fee reforms. In this climate, Hoya's
composite bone segment achieved sales growth of double-digit
year on year. By contrast, segment sales of chromatography
media, used in the refinement of biopharmaceutical
compounds, declined 30% compared to the previous year:
A
lthough, to be sure, this was because a big order from a major
customer was held up and booked after the fiscal year ended.
Given the global market for chromatography media has grown
at a rate of 10-15% annually, we expect steady expansion in
this business going forward.
A
gainst this market backdrop, New Ceramics saw earnings
increase on flat sales, as a result of initiatives the business took
to improve operational efficiency.
A
prosthetic filler for bone defects, APACERAM, Hoya's
mainstay in the apatite product category, is used mainly in the
fields of orthopedics, brain surgery and dentistry. A new solid-
type prosthetic filler, SUPERPORE™, was launched in July
2010 and went on to meet initial sales targets as of the end of
the term. This achievement was the combined result of exceptional product strength and swift
marketing. The Company also launched a new paste-type prosthetic filler, BIOPEX® ADVANCE,
which reaches maximum strength in just 12 hours after surgery. This gained kudos for greatly
improving the quality of life of patients, by enabling them to rise up the day after surgery. Sales
of this product were also strong.
The goals during the fiscal year under review for the business division were to expand market
share, maintain a highly profitable operating structure and to enter the market for metallic
implants. Market share increased from the launch of promising new products and vigorous
marketing initiatives. The division was also successful in enhancing the profitability of its
operations. Unfortunately, the other goal of entering the market for metallic implants went
unachieved.
Outlook for Fiscal 2012
The composite bone market is expected to see stable growth over the long term. In fiscal 2012,
Hoya will strive to build on the momentum of SUPERPORE™ and BIOPEX® ADVANCE and
increase sales in this business category 15% year on year. The Company will focus in particular
SUPERPORE™
BIOPEX® ADVANCE
Market share in Japan
(apatite products)